Literature DB >> 9628469

Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions.

J E Simpson1, J Newcombe, M L Cuzner, M N Woodroofe.   

Abstract

Beta-chemokines induce the directional migration of monocytes and T lymphocytes and are thus associated with chronic inflammation. Using immunocytochemistry and in situ hybridisation (ISH) techniques, we have examined the expression of the beta-chemokines monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory protein (MIP)-1alpha, MIP-1beta, and RANTES (regulated upon activation, normal T cell expressed and secreted) in post-mortem human brain from multiple sclerosis (MS) cases, at different stages of lesion development. In actively demyelinating MS plaques RANTES expression was restricted to the blood vessel endothelium, perivascular cells and surrounding astrocytes, suggesting a role in the recruitment of inflammatory cells from the circulation. MCP-1 was expressed by astrocytes and macrophages within acute MS lesions, but was restricted to reactive astrocytes in the parenchyma surrounding the lesion. MIP-1alpha was expressed by astrocytes and macrophages within the plaque, while MIP-1beta was expressed by macrophages and microglia within the lesion, and by microglia in surrounding white matter. Glial cells may be stimulated to produce chemokines and continue the local inflammatory response by forming chemotactic gradients to attract T cells and mononuclear phagocytes from the circulation and surrounding tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9628469     DOI: 10.1016/s0165-5728(97)00208-7

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  116 in total

Review 1.  Chemokines and central nervous system disorders.

Authors:  W J Karpus
Journal:  J Neurovirol       Date:  2001-12       Impact factor: 2.643

2.  Macrophage inflammatory protein-1alpha (MIP-1alpha), MIP-1beta, and RANTES mRNA semiquantification and protein expression in active demyelinating multiple sclerosis (MS) lesions.

Authors:  L A Boven; L Montagne; H S Nottet; C J De Groot
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

Review 3.  [Chemokine--possible new options for the treatment of multiple sclerosis].

Authors:  C Trebst; R M Ransohoff; A Windhagen; M Stangel
Journal:  Nervenarzt       Date:  2003-10       Impact factor: 1.214

Review 4.  Chemokines and glial cells: a complex network in the central nervous system.

Authors:  Elena Ambrosini; Francesca Aloisi
Journal:  Neurochem Res       Date:  2004-05       Impact factor: 3.996

5.  Expression of astrocytic type 2 angiotensin receptor in central nervous system inflammation correlates with blood-brain barrier breakdown.

Authors:  Laila Füchtbauer; Henrik Toft-Hansen; Reza Khorooshi; Trevor Owens
Journal:  J Mol Neurosci       Date:  2010-04-23       Impact factor: 3.444

Review 6.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

Review 7.  Janus head: the dual role of HLA-G in CNS immunity.

Authors:  Yu-Hwa Huang; Laura Airas; Nicholas Schwab; Heinz Wiendl
Journal:  Cell Mol Life Sci       Date:  2010-11-18       Impact factor: 9.261

8.  N-type calcium channel in the pathogenesis of experimental autoimmune encephalomyelitis.

Authors:  Naoki Tokuhara; Kana Namiki; Mai Uesugi; Chihiro Miyamoto; Makoto Ohgoh; Katsutoshi Ido; Takashi Yoshinaga; Toshihiko Yamauchi; Junro Kuromitsu; Sadao Kimura; Norimasa Miyamoto; Yoshitoshi Kasuya
Journal:  J Biol Chem       Date:  2010-08-18       Impact factor: 5.157

9.  Estrogen mediates neuroprotection and anti-inflammatory effects during EAE through ERα signaling on astrocytes but not through ERβ signaling on astrocytes or neurons.

Authors:  Rory D Spence; Amy J Wisdom; Yuan Cao; Haley M Hill; Chandler R L Mongerson; Briana Stapornkul; Noriko Itoh; Michael V Sofroniew; Rhonda R Voskuhl
Journal:  J Neurosci       Date:  2013-06-26       Impact factor: 6.167

10.  Glatiramer acetate treatment normalized the monocyte activation profile in MS patients to that of healthy controls.

Authors:  Delgertsetseg Chuluundorj; Scott A Harding; David Abernethy; Anne Camille La Flamme
Journal:  Immunol Cell Biol       Date:  2016-10-03       Impact factor: 5.126

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.